Vnitr Lek 2007, 53(9):1000-1002

Primary aldosteronism

A. Tokárčiková
IV. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, Ph.D.

Primary aldosteronism is caused by autonomous overproduction of aldosteron in the adrenocortical cells of zona glomerulosa. It is the most frequent form of endocrine hypertension. The morphologic base of this disorder are tumorous, or hyperplastic changes of the adrenal gland. Syndrome is divided into more well-defined pathogenetic forms. Therapy that we use is conservative, or surgical. Success of treatment depends on the correct diagnosis of pathogenetic form and on the duration of hypertension.

Keywords: primary aldosteronism; pathogenetic forms; drug therapy; adrenalectomy

Received: April 7, 2007; Published: September 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tokárčiková A. Primary aldosteronism. Vnitr Lek. 2007;53(9):1000-1002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J jr, Zelinka T. Endokrinní hypertenze. In: Widimský J et al. Hypertenze. Praha: Triton 2004: 518-540.
    2. William FY jr. Adrenal Cortex Hypertension. In: Oparil S, Weber MA. Hypertension. Philadephia: Elsevier Saunders 2005: 792-806. Go to original source...
    3. Tokárčiková A. Endokrinne podmienené hypertenzie. In: Jonáš P et al. Artériová hypertenzia v praxi. Košice: Maxdorf 2001: 212-225.
    4. Balažovjech I. Hypertenzie podmienené ochorením nadobličky. In: Balažovjech I. Artériová hypertenzia. Martin: Osveta 1999: 322-331.
    5. Edwards ChRW. Primary Mineralocorticoid Excess Syndromes. In: DeGroot LJ, Jameson JL et al. Endocrinology. Philadelphia: WB Saunders Company 2001: 1820-1844.
    6. Janota T, Widimský J, Král J et al. Structural heart changes in primary hyperaldosteronism and their reversibility. Eur Heart J 1998; 19: 423.
    7. Calhoun DA. Resistant Hypertension. In: Oparil S, Weber MA. Hypertension. Philadelphia: Elsevier Saunders 2005: 616-623. Go to original source...
    8. Kreze A sr. Hyperfunkcia kôry nadobličiek. In: Kreze A et al. Všeobecná a klinická endokrinológia. Bratislava: AEP 2004: 373-392.
    9. Fardella CE, Mosso L, Gómez-Sánchez C et al. Primary hyperaldosteronism in essential hypertension: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867. Go to original source...
    10. Ganguly A. Primary aldosteronism. New Engl J Med 1998; 339: 1828-1834. Go to original source... Go to PubMed...
    11. Vallotton MB. Primary aldosteronism. Part I. Diagnosis of primary aldosteronism. Clinical Endocrinology 1996; 45: 47-52. Go to original source... Go to PubMed...
    12. Streeten DHP, Anderson GH jr. Aldosterone disorders. In: Moore WT, Eastman RC. Diagnostic endocrinology. St. Louis: Mosby 1996: 283-298.
    13. Puccini M, Iacconi P et al. Conn Syndrome: 14 Year's Experience from Two European Centres. Eur J Surg 1998; 164: 811-817. Go to original source... Go to PubMed...
    14. Dluhy RG, Lawrence JE, Williams GH. Endocrine Hypertension. In: Larsen PR, Kronenberg HM, Melmed S et al. Philadelphia: WB Saunders 2003: 552-585.
    15. Proye ChAG, Mulliez EAR et al. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998; 124: 1128-1133. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.